Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment

Abstract

The first treatments showing effectiveness for some psychiatric disorders, such as lithium for bipolar disorder and chlorpromazine for schizophrenia, were discovered by accident. Currently, psychiatric drug design is seen as a scientific enterprise, limited though it remains by the complexity of brain development and function. Relatively few novel and effective drugs have, however, been developed for many years. The purpose of this article is to demonstrate how evolutionary biology can provide a useful framework for psychiatric drug development. The framework is based on a diametrical nature of autism, compared with psychotic-affective disorders (mainly schizophrenia, bipolar disorder and depression). This paradigm follows from two inferences: (i) risks and phenotypes of human psychiatric disorders derive from phenotypes that have evolved along the human lineage and (ii) biological variation is bidirectional (e.g. higher vs lower, faster vs slower, etc.), such that dysregulation of psychological traits varies in two opposite ways. In this context, the author review the evidence salient to the hypothesis that autism and psychotic-affective disorders represent diametrical disorders in terms of current, proposed and potential psychopharmacological treatments. Studies of brain-derived neurotrophic factor, the PI3K pathway, the NMDA receptor, kynurenic acid metabolism, agmatine metabolism, levels of the endocannabinoid anandamide, antidepressants, anticonvulsants, antipsychotics, and other treatments, demonstrate evidence of diametric effects in autism spectrum disorders and phenotypes compared with psychotic-affective disorders and phenotypes. These findings yield insights into treatment mechanisms and the development of new pharmacological therapies, as well as providing an explanation for the longstanding puzzle of antagonism between epilepsy and psychosis.Lay Summary: Consideration of autism and schizophrenia as caused by opposite alterations to brain development and function leads to novel suggestions for pharmacological treatments.

Are Fecal Metabolome and Microbiota Profiles Correlated with Autism Severity? A Cross-Sectional Study on ASD Preschoolers

“…In fact, dysfunctional ionotropic NMDA receptors have been recently linked to multiple forms of ASD and emerging evidence showed that d-aspartate and d-serine are important neuromodulators of glutamatergic transmission [ 19 ]. These data suggest that targeting the NMDA receptor could have promising therapeutic potential in ASDs and experimental studies have been conducted with this aim [ 20 ].…”

Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond

“…“The emerging, remarkable confluence of data from humans and animals suggests an opportunity for developing a rational pharmacology by targeting cortical KP metabolism for cognition enhancement in schizophrenia and beyond ” (Wonodi & Schwarcz, 2010). KYNA is the next frontier for neuropsychiatric diseases; the KP was described as a finger in every pie recently (Crespie, 2019; Savitz, 2020). KYNA‐centric pathophysiology (Koola, 2020) may be of considerable value in the treatment of many neuropsychiatric diseases.…”

Why iPlay: The Relationships of Autistic and Schizotypal Traits With Patterns of Video Game Use

“…Second, according to the diametric model of social brain disorders ( Crespi and Badcock, 2008 ; Crespi and Go, 2015 ; Crespi, 2016 , 2019 , 2020 ), autism and psychosis can be conceptualized as polar ends of a continuum of social cognition development, with normality at its center. Thus, autism is characterized by low mentalistic thought (i.e., social cognition) and high mechanistic thought (i.e., non-social cognition), and psychotic-affective conditions, such as schizotypy, are characterized by high mentalistic and low mechanistic thought ( Crespi and Badcock, 2008 ).…”